Lean oncology: a new model for oncologists

nork Montesarchio, Vincenzo, Grimaldi, Antonio Maria, Fox, Bernard A, Rea, Antonio, Marincola, Francesco M, Ascierto, Paolo A
Argitaratua 2012

Do BRAF inhibitors select for populations with different disease progression kinetics?

nork Ascierto, Paolo Antonio, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola
Argitaratua 2013

Serious haematological toxicity during and after ipilimumab treatment: a case series

nork Simeone, Ester, Grimaldi, Antonio Maria, Esposito, Assunta, Curvietto, Marcello, Palla, Marco, Paone, Miriam, Mozzillo, Nicola, Ascierto, Paolo Antonio
Argitaratua 2014

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma

nork Stucci, Stefania, Tucci, Marco, Ascierto, Paolo Antonio, Passarelli, Anna, Mariaelena, Capone, Madonna, Gabriele, Ester, Simeone, Grimaldi, Antonio Maria, Silvestris, Franco
Argitaratua izan da J Transl Med (2015)

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series

nork Di Monta, Gianluca, Caracò, Corrado, Marone, Ugo, Grimaldi, Antonio Maria, Anniciello, Anna Maria, Di Marzo, Massimiliano, Simeone, Ester, Mori, Stefano
Argitaratua izan da BMC Res Notes (2015)

UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR)

nork Montella, Maurizio, Gandini, Sara, Rossi, Carlo Riccardo, Testori, Alessandro, Mastrangelo, Giuseppe, Serraino, Diego, Budroni, Mario, Crispo, Anna, Grimaldi, Antonio Maria, Ascierto, Paolo Antonio
Argitaratua 2014

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report

nork Falivene, Sara, Giugliano, Francesca Maria, Grimaldi, Antonio Maria, Di Franco, Rossella, Toledo, Diego, Muto, Matteo, Cammarota, Fabrizio, Borzillo, Valentina, Ascierto, Paolo Antonio, Muto, Paolo
Argitaratua 2014

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

nork Simeone, Ester, Grimaldi, Antonio Maria, Festino, Lucia, Giannarelli, Diana, Vanella, Vito, Palla, Marco, Curvietto, Marcello, Esposito, Assunta, Palmieri, Giuseppe, Mozzillo, Nicola, Ascierto, Paolo Antonio
Argitaratua izan da Oncoimmunology (2017)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients

nork Grimaldi, Antonio Maria, Simeone, Ester, Festino, Lucia, Giannarelli, Diana, Palla, Marco, Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Grimaldi, Maria Chiara, Mozzillo, Nicola, Ascierto, Paolo A
Argitaratua izan da J Immunother Cancer (2015)

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters

nork Simeone, Ester, Benedetto, Lucia, Gentilcore, Giusy, Capone, Marilena, Caracò, Corrado, Di Monta, Gianluca, Marone, Ugo, Di Cecilia, Marialuisa, Grimaldi, Antonio Maria, Mori, Stefano, Mozzillo, Nicola, Ascierto, Paolo A
Argitaratua 2014

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis

nork Di Monta, Gianluca, Caracò, Corrado, Simeone, Ester, Grimaldi, Antonio Maria, Marone, Ugo, Di Marzo, Massimiliano, Vanella, Vito, Festino, Lucia, Palla, Marco, Mori, Stefano, Mozzillo, Nicola, Ascierto, Paolo Antonio
Argitaratua izan da J Transl Med (2017)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

nork Capone, Mariaelena, Giannarelli, Diana, Mallardo, Domenico, Madonna, Gabriele, Festino, Lucia, Grimaldi, Antonio Maria, Vanella, Vito, Simeone, Ester, Paone, Miriam, Palmieri, Giuseppe, Cavalcanti, Ernesta, Caracò, Corrado, Ascierto, Paolo Antonio
Argitaratua izan da J Immunother Cancer (2018)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients

nork Simeone, Ester, Grimaldi, Antonio Maria, Festino, Lucia, Giannarelli, Diana, Palla, Marco, Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Paone, Miriam, Rinaldi, Giovanni, Grimaldi, Maria Chiara, Mozzillo, Nicola, Ascierto, Paolo A
Argitaratua izan da J Immunother Cancer (2015)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib

nork Queirolo, Paola, Spagnolo, Francesco, Picasso, Virginia, Spano, Laura, Tanda, Enrica, Fontana, Valeria, Giorello, Laura, Merlo, Domenico Franco, Simeone, Ester, Grimaldi, Antonio Maria, Curvietto, Marcello, Del Vecchio, Michele, Bruzzi, Paolo, Ascierto, Paolo Antonio
Argitaratua izan da Oncotarget (2016)

The Ratio of GrzB(+) − FoxP3(+) over CD3(+) T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma

nork Scognamiglio, Giosuè, Capone, Mariaelena, Sabbatino, Francesco, Di Mauro, Annabella, Cantile, Monica, Cerrone, Margherita, Madonna, Gabriele, Grimaldi, Antonio Maria, Mallardo, Domenico, Palla, Marco, Sarno, Sabrina, Anniciello, Anna Maria, Di Bonito, Maurizio, Ascierto, Paolo Antonio, Botti, Gerardo
Argitaratua izan da Cancers (Basel) (2021)

Clinical trials and drug cost savings for Italian health service

nork D’Ambrosio, Francesca, De Feo, Gianfranco, Botti, Gerardo, Capasso, Arturo, Pignata, Sandro, Maiolino, Piera, Triassi, Maria, Nardone, Antonio, Perrone, Franco, Piezzo, Michela, Grimaldi, Antonio Maria, Palazzo, Ida, De Stasio, Immacolata, D’Aniello, Roberta, Morabito, Alessandro, Pascarella, Giacomo
Argitaratua izan da BMC Health Serv Res (2020)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

nork Daponte, Antonio, Signoriello, Simona, Maiorino, Luigi, Massidda, Bruno, Simeone, Ester, Grimaldi, Antonio Maria, Caracò, Corrado, Palmieri, Giuseppe, Cossu, Antonio, Botti, Gerardo, Petrillo, Antonella, Lastoria, Secondo, Cavalcanti, Ernesta, Aprea, Pasquale, Mozzillo, Nicola, Gallo, Ciro, Comella, Giuseppe, Ascierto, Paolo Antonio
Argitaratua 2013

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab

nork Simeone, Ester, Romano, Maria fiammetta, Grimaldi, Antonio Maria, Esposito, Assunta, Curvietto, Marcello, Paone, Miriam, Rinaldi, Giovanni, Di monta, Gianluca, Di marzo, Massimiliano, Hauber, Federica, Festino, Lucia, D'Angelillo, Anna, Romano, Simona, Staibano, Stefania, Ilardi, Gennaro, Bisogni, Rita, Mozzillo, Nicola, Ascierto, Paolo Antonio
Argitaratua izan da J Immunother Cancer (2014)

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

nork Chiarion Sileni, Vanna, Pigozzo, Jacopo, Ascierto, Paolo Antonio, Grimaldi, Antonio Maria, Maio, Michele, Di Guardo, Lorenza, Marchetti, Paolo, de Rosa, Francesco, Nuzzo, Carmen, Testori, Alessandro, Cocorocchio, Emilia, Bernengo, Maria Grazia, Guida, Michele, Marconcini, Riccardo, Merelli, Barbara, Parmiani, Giorgio, Rinaldi, Gaetana, Aglietta, Massimo, Grosso, Marco, Queirolo, Paola
Argitaratua 2014

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

nork Montesarchio, Vincenzo, Parrella, Roberto, Iommelli, Chiara, Bianco, Antonella, Manzillo, Elio, Fraganza, Fiorentino, Palumbo, Cristiana, Rea, Gaetano, Murino, Patrizia, De Rosa, Rosanna, Atripaldi, Luigi, D’Abbraccio, Maurizio, Curvietto, Marcello, Mallardo, Domenico, Celentano, Egidio, Grimaldi, Antonio Maria, Palla, Marco, Trojaniello, Claudia, Vitale, Maria Grazia, Million-Weaver, Samuel Lewis, Ascierto, Paolo Antonio
Argitaratua izan da J Immunother Cancer (2020)